Evidence to Practice : State of the art CKD Care with SLGT2-inhibitors.

Speciality: Nephrology

Description:

A warm welcome to all the medical professionals in this interesting session on Evidence to Practice: State of the art CKD Care with SLGT2- inhibitors use of SGLT2 inhibitors represents a groundbreaking advance in the management of chronic kidney disease (CKD), supported by robust clinical evidence. These agents, originally developed for glycemic control in diabetes, have demonstrated significant renoprotective effects, including slowing CKD progression, reducing albuminuria, and lowering the risk of cardiovascular events. Landmark trials like DAPA-CKD and EMPA-KIDNEY highlight their efficacy in both diabetic and non-diabetic CKD populations.
In clinical practice, the integration of SGLT2 inhibitors has shifted the paradigm of CKD care toward early intervention and comprehensive risk reduction. Beyond renal benefits, their safety profile and ability to mitigate heart failure risks make them a preferred choice for multimorbidity management in CKD patients. Ongoing research aims to expand their application and refine treatment strategies for broader populations.
Therefore, get an overall knowledge Evidence to Practice : State of the art CKD Care with SLGT2- inhibitors. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.
 

See More Webinars @ Hidoc Webinars